22 results about "Egfr mutation" patented technology

The application belongs to the field of diagnosis and treatment, and particularly relates to a lung cancer EGFR mutation non-invasive prediction model based on unsupervised decoupling and gate fusion. A multi-modal fusion model is constructed based on enhanced CT images and clinical data of non-small cell lung cancer patients. The application adopts a mask image modeling task, and autonomously learns morphological and texture primitive features of tumors from three-dimensional enhanced CT images without EGFR mutation labels. The application overcomes the dependence on a large amount of labeled data, enables the model to learn visual representations with high discriminability and generalization ability from unlabeled data, and significantly improves feature expression capability. A multi-modal fusion architecture based on a gate mechanism is designed, which can dynamically adjust the contribution weights of deep features, imaging features and clinical information in different samples. Personalized feature fusion for different cases is realized, the limitations of traditional static fusion methods are overcome, and complementary information between multi-source heterogeneous data is fully mined.

The application discloses a heterocyclic EGFR mutation inhibitor in the field of pharmaceutical chemistry, which is a heterocyclic compound shown in general formula I or a stereoisomer or optical isomer thereof or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, p, X, Y, Z, W, Cy1 and Cy2 are as defined in the claims. The main effect of the heterocyclic EGFR mutation inhibitor is to exert an antitumor effect by inhibiting a mutant EGFR.

The application belongs to the field of biomedicine, and particularly relates to application of fibroblasts in disease treatment; and specifically discloses application of ANXA6 gene in preparation of a diagnostic preparation for treating EGFR mutation-mediated diseases, wherein when overexpression of the ANXA6 gene in CAF cells is detected, the EGFR mutation-mediated diseases cannot be treated by using EGFR targeted drugs; further, the EGFR targeted drugs are epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).

This invention belongs to the field of tumor biology and drug screening technology, specifically disclosing a human EGFR mutation-driven mouse primary lung cancer cell line, its construction method, and its applications. The cell line, ZST-1, is a human EGFR (L858R / T790M) mutation-driven lung cancer cell line derived from mouse primary lung cancer. It is stable, capable of subcutaneous tumor formation in C57BL / 6 mice, and simultaneously expresses Luciferase and tdTomato reporter genes. Its construction method includes obtaining transgenic mice, virus-induced tumor formation, continuous in vivo passage in nude mice, and in vitro culture and screening steps. This cell line can be applied to in vitro screening and efficacy evaluation of human EGFR mutation-targeting drugs, research on EGFR-TKI resistance mechanisms, tumor bioluminescence imaging and fluorescence tracing, and in vivo tumorigenesis and efficacy experiments in an immune-intact C57BL / 6 background.

The invention relates to an application of osimertinib combined with chidamide in treatment of osimertinib drug-resistant lung cancer, and particularly relates to the following aspects: (1) osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and shows a remarkable curative effect in treatment of non-small cell lung cancer (NSCLC) patients carrying specific EGFR mutation; (2) chidamide is a novel oral HDACi, can induce cell apoptosis, cell cycle arrest and cell growth inhibition, and shows good tolerance and antitumor activity in various cancer types; and (3) chidamide is taken as an epigenetic regulating agent and can be in synergistic effect with osimertinib, so that the capability of killing lung cancer cells is enhanced. The invention belongs to the technical field of medicines, and particularly provides application of osimertinib combined with chidamide in treatment of osimertinib drug-resistant lung cancer.

This invention relates to a system, kit, and application for the one-pot detection of miRNA and DNA mutations based on CRISPR-Cas12a and aptamers, belonging to the field of biomedical technology. The system for the one-pot detection of miRNA and DNA mutations based on CRISPR-Cas12a and aptamers includes: Cas12a protein, crRNA-R targeting miRNA, aptamer P1, aptamer P2, a linker, AO, and crRNA-D targeting DNA mutations. This invention combines CRISPR / Cas12a with a aptamer-based detection strategy to develop a label-free, direct detection system compatible with smartphones. This system can simultaneously detect EGFR mutations and miRNA-21 expression levels.

This invention discloses a bivalent ligand molecule targeting EGFR and its applications, belonging to the field of drug development technology. Its general structural formula is: [Formula omitted for brevity], where L is a linking group, and M1 and M2 are EGFR protein ligands. This invention forms a bivalent EGFR ligand molecule by covalently linking two EGFR ligands through a linking group. This bivalent ligand molecule can induce additional protein-protein interactions between EGFR monomers, which greatly enhances the binding strength and stability of the drug to EGFR, thereby overcoming the drug resistance problem of traditional EGFR inhibitors and providing a new treatment strategy for cancer patients carrying EGFR mutations and other patients with other diseases.

The present invention relates to treatment of subjects having EGFR exon 20 insertion and other uncommon EGFR mutations.

The present invention relates to treatment of subjects having EGFR exon 20 insertion and other uncommon EGFR mutations.

The present invention relates to N4-(indolin-7-yl)-N2-(2-alkoxypyridin-3-yl)pyrimidine-2,4-diamine derivatives, a method for preparing same, and a pharmaceutical composition for the prevention or treatment of cancer comprising same as an active ingredient. The pyrimidine derivatives of the present invention exhibit high inhibitory activity against EGFR mutation and HER2 mutation and thus can be usefully employed in the treatment of cancers involving EGFR or HER2 mutations.

The present disclosure relates to an engineered T-cell Receptors (TCRs) capable of binding to an epitope of an epidermal growth factor receptor (EGFR) comprising a T790M mutation presented on human leukocyte antigen-A (HLA-A)*02:01, wherein the epitope comprises the amino acid sequence of MQLMPFGCLL (SEQ ID NO: 1). Also disclosed are Tcell and BiTE therapies comprising the same, and methods of treating EGFR-TKI resistant lung cancers using the same.

The embodiment of the invention provides a bifunctional micro-fluidic chip for guiding cancer medication, a preparation method and a detection method. The chip comprises a substrate, a cell processing layer and a substance injection layer which are sequentially stacked, the substance injection layer is communicated with the cell treatment layer; the cell processing layer comprises a cell mutation detection module and an organoid analysis module, and the substance injection layer comprises a drug injection module; the cell mutation detection module is used for capturing and detecting the type of injected cancer cells; the drug injection module is used for providing a corresponding anti-cancer drug for the organoid analysis module according to the type of injected cancer cells; and the organoid analysis module is used for culturing the injected cancer cells into organoid and monitoring the medication reaction of the organoid in real time. According to the chip, a feasible solution combining cell EGFR mutation detection and organoid-based drug reaction test is realized, and the chip can be used for guiding personalized lung cancer drug treatment.

The invention provides a digital PCR (polymerase chain reaction) method for detecting EGFR (epidermal growth factor receptor) mutation based on a micro-fluidic chip, and relates to the technical field of digital PCR detection.The method comprises the following steps: providing sample DNA (deoxyribonucleic acid); preparing a digital PCR reaction system containing a specific primer probe; adding a sample of the system to a micro-fluidic array chip to generate more than 20,000 micro-reaction units; carrying out PCR (Polymerase Chain Reaction) amplification; fluorescence signals of four channels of FAM, HEX, ROX and CY5 are detected; and interpreting the result according to a specific standard. Key parameters of the platform are determined for the first time, for example, the sample loading amount needs to be smaller than or equal to 105 wild copy / reaction, and a scientific interpretation threshold value is determined. The method is wide in linear range, low in detection limit, good in precision and high in high-frequency mutation consistency compared with NGS, low-frequency mutation which is difficult to find by the NGS can be effectively detected, and a standardized and high-sensitivity detection scheme is provided for NSCLC liquid biopsy.

The present invention relates to a benzamide derivative, a preparation method therefor, and a pharmaceutical composition comprising same as an active ingredient for prevention or treatment of cancer. The benzamide derivative provided in an aspect of the present invention can be used for preventing or treating cancer by suppressing EGFR mutation, and exhibits a remarkable synergy effect on anticancer activity when administered in combination with an EGFR antagonist such as Cetuximab, thus finding advantageous uses as an anticancer agent.

The present invention relates to a compound as represented by general formula (1), and a preparation method therefor, and the use of the compound as represented by general formula (1) and an isomer, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof as an EGFR inhibitor in the preparation of a drug against EGFR-related diseases, such as tumors.

This disclosure relates to the use of an EGFR inhibitor or a pharmaceutically acceptable salt thereof for the treatment of cancers having two or more EGFR mutations, wherein at least one of the mutations is a C797 mutation; preferably a C797S mutation. The EGFR inhibitors disclosed herein are compounds of formula (I): (I), or pharmaceutically acceptable salts, N-oxides, or solvates thereof.

The present disclosure relates to the use and methods of anti-HER3 antibody drug conjugates for the treatment of tumors. Specifically, the invention relates to application of the anti-HER3 antibody drug conjugate in preparation of drugs for treating EGFR mutation tumors, and the anti-HER3 antibody drug conjugate has a structure as shown in a formula I. The invention further relates to a preparation method of the anti-HER3 antibody drug conjugate.

The invention discloses an LLC cell mEgfrp.L860R mutant strain Mus musculus and application of the LLC cell mEgfrp.L860R mutant strain Mus musculus, and belongs to the technical field of cell engineering. According to the LLC cell mEgfrp.L860R mutant strain Mus musculus, on the basis of an LLC cell line, by accurately introducing EGFR typical mutation, the clinical state of an EGFR mutant NSCLC patient is successfully simulated. Compared with a traditional EGFR mutant cell model, the LLC cell mEgfrp.L860R mutant strain Mus musculus not only has a stable EGFR mutant phenotype, but also can well reflect the dynamic change of the immune microenvironment of tumor cells in the EGFR-TKI process, provides a powerful in-vitro and in-vivo experimental tool for researching the construction of the tumor immune microenvironment using EGFR-TKI, and has an important clinical transformation value.

The present application relates to the technical field of biological medicine, and provides a lung cancer combined treatment composition, which comprises a C1GALT1 inhibiting drug and a Tn antigen related immunotherapy agent.The advantages are as follows: (1) the present application significantly improves the treatment effect on lung cancer through the synergistic effect of the C1GALT1 inhibition and the Tn related immunotherapy agent, provides a new treatment scheme for improving the clinical prognosis of lung cancer with EGFR mutation, and provides a new research direction for lung cancer treatment; (2) it is revealed that the EGFR TKI targeted drug inhibits the expression of C1GALT1 through the PI3K / AKT / SP1 pathway, blocks the subsequent glycosylation process of the Tn antigen, and up-regulates the expression of the Tn antigen in tumor cells, which indicates that the combination of the Tn antigen and the immunotherapy agent can improve the anti-lung cancer effect.

The present application provides methods of treating cancer in an individual in need thereof, wherein in the cancer in the individual has been determined to comprise one or more atypical epidermal growth factor receptor (EGFR) mutations, comprising administering to the individual (R)-N-(2-(4-(4-cyclopropylpiperazin-l-yl)piperidin-l-yl)-5-((6-(3-(3,5- difluorophenyl)isoxazolidin-2-yl)pyrimidin-4-yl)amino)-4-methoxyphenyl)acrylamide, or a pharmaceutically acceptable salt thereof.

The present disclosure relates to methods for treating or preventing non-small cell lung cancer in a patient, wherein the non-small cell lung cancer has a targetable EGFR mutation, the method comprising administering to the patient an immunoconjugate of Formula (I): (I), wherein: Ab is an antibody that binds to TROP-2; and n is an integer from 1 to 10. Also disclosed are combination therapies and kits comprising such agents for the treatment of cancer.